Patents by Inventor Jesse Roth

Jesse Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Toe protecting cushion device
    Patent number: 9504593
    Abstract: Toe cushioning device for protecting a patient's toes. A toe cushion device includes two tubular cushions positioned in a transverse plane on the plantar side of a patient's toes during use. The toe cushion relieves foot or toe pain and conforms to the changing contour of the patient's foot and toes during use.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: November 29, 2016
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Jesse Roth, Gordon J. Berg
  • Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication
    Publication number: 20150366852
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: June 23, 2015
    Publication date: December 24, 2015
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Michael Brownstein, Kálmán Takács, Laszlo Vigh, József Mandl, Balázs Sümegi, Sandor Bernath, Attila Kolonics, Gábor Balogh, Janos Egri
  • TOE PROTECTING CUSHION DEVICE
    Publication number: 20140213954
    Abstract: Toe cushioning device for protecting a patient's toes. A toe cushion device includes two tubular cushions positioned in a transverse plane on the plantar side of a patient's toes during use. The toe cushion relieves foot or toe pain and conforms to the changing contour of the patient's foot and toes during use.
    Type: Application
    Filed: January 28, 2014
    Publication date: July 31, 2014
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Jesse Roth, Gordon J. Berg
  • Peptide mimics of melanocyte stimulating hormone
    Patent number: 8080632
    Abstract: Provided are peptides having melanocyte stimulating hormone activity. Also provided are vectors encoding these peptides and transgenic cells comprising the above vectors. Additionally, methods of reducing or preventing release of an inflammatory cytokine from mammalian cells are provided, as are methods for treating a mammal suffering from, or at risk for, a condition mediated by an inflammatory cytokine cascade. Further provided are methods of reducing levels of an inflammatory cytokine in a mammal, methods of treating an overweight mammal, methods of decreasing food intake in a mammal and methods of inhibiting innate immunity in the digestive system of a mammal.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: December 20, 2011
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Jesse Roth
  • Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication
    Publication number: 20100311719
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: August 17, 2010
    Publication date: December 9, 2010
    Inventors: Péter Literáti Nagy, Jesse Roth, Zoltán Szilvássy, Kálmán Tory, Mike Brownstein, Kálmán Takács, László Vígh, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
  • Peptide mimics of melanocyte stimulating hormone
    Publication number: 20100048465
    Abstract: Provided are peptides having melanocyte stimulating hormone activity. Also provided are vectors encoding these peptides and transgenic cells comprising the above vectors. Additionally, methods of reducing or preventing release of an inflammatory cytokine from mammalian cells are provided, as are methods for treating a mammal suffering from, or at risk for, a condition mediated by an inflammatory cytokine cascade. Further provided are methods of reducing levels of an inflammatory cytokine in a mammal, methods of treating an overweight mammal, methods of decreasing food intake in a mammal and methods of inhibiting innate immunity in the digestive system of a mammal.
    Type: Application
    Filed: September 1, 2006
    Publication date: February 25, 2010
    Inventor: Jesse Roth
  • Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
    Publication number: 20090281143
    Abstract: O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.
    Type: Application
    Filed: December 10, 2008
    Publication date: November 12, 2009
    Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Attila Kolonics, Sandor Bernath, Laszlo Vigh, Jesse Roth, G. Alexander Fleming, Michael Brownstein, Janos Egri
  • Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
    Publication number: 20080108602
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 8, 2008
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Mike Brownstein, Kalman Takacs, Laszlo Vigh, Jozsef Mandi, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
  • Polypeptide for obesity and type II diabetes mellitus
    Patent number: 5877283
    Abstract: The present invention provides a novel polypeptide characterized by a non-conservative missense mutation, Trp64Arg, in the .beta.3-adrenergic receptor (.beta.3AR) that increases susceptibility to obesity and non-insulin dependent diabetes mellitus (NIDDM; type II diabetes). Also provided are methods of diagnosis and methods of treatment of subjects having or at risk of having type II diabetes/obesity.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: March 2, 1999
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Alan R. Shuldiner, Jeremy Walston, Kristi Silver, Jesse Roth
  • Susceptibility gene for obesity and type II diabetes mellitus
    Patent number: 5766851
    Abstract: The present invention provides a novel polypeptide characterized by a non-conservative missense mutation, Trp64Arg, in the .beta.3-adrenergic receptor (.beta.3AR) that increases susceptibility to obesity and non-insulin dependent diabetes mellitus (NIDDM; type II diabetes). Also provided are methods of diagnosis and methods of treatment of subjects having or at risk of having type II diabetes/obesity.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: June 16, 1998
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Alan R. Shuldiner, Jeremy Walston, Kristi Silver, Jesse Roth